
Guidance for Industry

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)

December 2020
Electronic Submissions

Additional copies are available from:
Office of Communications, Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration
10001 New Hampshire Ave., Hillandale Bldg., 4th Floor
Silver Spring, MD 20993-0002
Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353
Email: druginfo@fda.hhs.gov

and/or
Office of Communication, Outreach and Development
Center for Biologics Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 71, Room 3128
Silver Spring, MD 20993-0002
Phone: 800-835-4709 or 240-402-8010
Email: ocod@fda.hhs.gov

https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)

December 2020
Electronic Submissions
# TABLE OF CONTENTS

I. INTRODUCTION.......................................................................................................................... 1

II. BACKGROUND .......................................................................................................................... 2

III. REQUIREMENT TO SUBMIT ELECTRONICALLY UNDER THIS GUIDANCE ......................................................... 2

A. Types of Submissions That Must Adhere to the Electronic Submission Requirement
   Described in This Guidance........................................................................................................... 2

B. Requirements That Must Be Followed for Electronic Submission of the Content of REMS Documents...................................................................................................................................................... 3

C. Types of Submissions That Are Exempt From the Electronic Submission Requirement
   Described in This Guidance........................................................................................................... 4

D. SPL Specifications....................................................................................................................... 4

E. Contact Information.................................................................................................................... 4

I. INTRODUCTION

Under section 745A(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 379k-1(a)), beginning no earlier than 24 months after the issuance of this final guidance in which the Food and Drug Administration (FDA or Agency) has specified the electronic format for submitting certain submission types to the Agency, the content of such submission types must be submitted electronically and in the format specified by FDA. This guidance describes the format requirements for the electronic submission of the content of a risk evaluation and mitigation strategy (REMS) document under section 745A(a) of the FD&C Act. This guidance describes how FDA will implement the requirements for the electronic submission of REMS documents as part of submissions under new drug applications (NDAs), abbreviated new drug applications (ANDAs), and, as described in Section III below, certain biologics license applications (BLAs). Consistent with section 745A(a) of the FD&C Act, beginning 24 months after the issuance of this final guidance, REMS documents must be submitted to FDA in SPL format.

In section 745A(a) of the FD&C Act, Congress granted explicit authorization to FDA to implement the statutory electronic submission requirements in guidance. Accordingly, as indicated by the use of the words must or required, this guidance establishes legally enforceable responsibilities and is not subject to the usual restrictions in FDA’s good guidance practices (GGP) regulation (see 21 CFR 10.115(d)). To comply with the GGP regulations and make sure that regulated entities and the public understand that guidance documents are nonbinding, FDA guidances ordinarily contain standard language explaining that guidance documents should be viewed only as recommendations unless specific regulatory or statutory requirements are cited. FDA is not including this standard language in this guidance because it is not an accurate description of all the effects of this guidance. This guidance specifies the format for electronic submission of REMS documents under section 745A(a) of the FD&C Act, and will have binding effect 24 months from the date the notice of availability for this guidance is published in the Federal Register.

1 This guidance has been prepared by the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration.
2 See page 3 for more detail on which component of a REMS submission needs to be submitted in SPL format.
3 See also guidance for industry Providing Regulatory Submissions in Electronic Format — Submissions Under Section 745A(a) of the Federal Food, Drug, and Cosmetic Act (December 2014). We update guidances periodically. To make sure you have the most recent version of a guidance, check the FDA Drugs Guidance website at https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs.
II. BACKGROUND

FDA engaged stakeholders over a 3-year time frame and analyzed their feedback regarding REMS standardization. The Agency’s findings were published as a report: “Standardizing and Evaluating Risk Evaluation and Mitigation Strategies (REMS).” As the report describes, some stakeholders expressed concern about the clarity and consistency with which information about REMS materials and requirements are communicated to stakeholders. They told FDA that REMS materials and requirements may be difficult to locate, and that specific activities and requirements of various stakeholders (e.g., prescriber, pharmacist) are not always clearly outlined. Some stakeholders expressed the need to have better ways to integrate REMS materials and procedures into their existing health information systems and health care delivery processes. Stakeholders also expressed the desire to avoid spending excessive time trying to locate, understand, and comply with different REMS requirements while ensuring safe use of drugs with REMS. To help address these concerns, applicants of NDAs, ANDAs, and certain BLAs will be required to submit the content of their REMS documents in Structured Product Labeling (SPL) format. SPL can be used to capture and present REMS information in a format that is easily shared with stakeholders and readily incorporated into health information technology. For more general background information on REMS, as well as a more comprehensive discussion of the issues mentioned in this paragraph, please refer to the “Background Materials” for the July 2013 REMS Standardization and Evaluation Public Meeting.

III. REQUIREMENT TO SUBMIT ELECTRONICALLY UNDER THIS GUIDANCE

Twenty-four months after the publication of this guidance in the Federal Register, applicants must submit REMS documents in electronic format consistent with the requirements set forth below.

A. Types of Submissions That Must Adhere to the Electronic Submission Requirement Described in This Guidance

Section 745A(a) of the FD&C Act applies to submissions under section 505(b), (i), or (j) of the FD&C Act (21 U.S.C. 355(b), (i), or (j)) and under section 351(a) or (k) of the Public Health Service Act (PHS Act) (42 U.S.C. 262(a) or (k)). For the purposes of this guidance, these submissions include the following types:

- NDAs
- ANDAs

Contains Binding Provisions

- Certain BLAs\(^6,7\)

As stated in the guidance for industry *Providing Regulatory Submissions in Electronic Format – Submissions Under Section 745A(a) of The Federal Food, Drug, and Cosmetic Act*, “[s]ection 745A(a) also applies to all subsequent submissions, including amendments, supplements, and reports, to the submission types identified above.” Because they are part of a drug’s approval, REMS submissions are submissions under section 505(b), (i), or (j) of the FD&C Act or under section 351(a) or (k) of the PHS Act. Therefore, REMS submissions fall within the scope of requirements set forth in section 745A(a) of the FD&C Act.

Applicants must submit the content of their REMS document electronically using the format described in this guidance beginning 24 months from the date the notice of availability for this guidance is published. Accordingly, because the guidance issued on the date of publication of the notice of availability, December 28, 2020, all REMS documents submitted to FDA on or after December 28, 2022 must be in SPL format. This would include REMS documents associated with new REMS as well as REMS documents submitted as part of REMS modifications. In addition, beginning December 28, 2022, REMS revision submissions that include REMS documents that are already in SPL format must remain in SPL format, while REMS revision submissions that include REMS documents that have not yet been converted to SPL format do not need to be converted to SPL format until their next modification is submitted.

**B. Requirements That Must Be Followed for Electronic Submission of the Content of REMS Documents**

Under section 745A(a) of the FD&C Act, electronic submissions “shall be submitted in such electronic format as specified by [FDA].” This guidance addresses electronic submission requirements for certain documents that are part of a REMS. A *REMS document*, which is part of the REMS that is approved by FDA, concisely describes the goals and requirements of the REMS. FDA has determined that the content of a REMS document must be submitted electronically in SPL format, using specifications outlined in the FDA Data Standards Catalog.\(^8\) *REMS materials* are all materials that are included as part of the REMS (e.g., communication and educational materials, enrollment forms, prescriber and patient agreements) that are also approved and enforceable, and are appended to the REMS document. REMS materials must be

---

\(^6\) This guidance does not apply to those devices that are regulated by CBER as biological products under section 351 of the PHS Act, including those that do not require the submission of an investigational new drug application before the submission of a BLA. Although a discussion of which devices CBER regulates as biological products under section 351 of the PHS Act is outside the scope of this guidance, as a general matter, this category would include those reagents used in determining donor/recipient compatibility in transfusion medicine.

\(^7\) Specifically, this guidance is not applicable to submissions for blood and blood components, including Source Plasma.

\(^8\) The most current version of the Data Standard Catalog is available at [https://www.fda.gov/industry/fda-resources-data-standards](https://www.fda.gov/industry/fda-resources-data-standards).
referenced in the SPL file. REMS supporting documents are not required to be submitted in SPL format. The table below shows which components of a REMS will be required to be filed in SPL format. Additional details for creating REMS document SPL files for submission to FDA can be found in the “Structured Product Labeling (SPL) Implementation Guide with Validation Procedures” (SPL Implementation Guide) on FDA’s SPL website. Details for the placement of the REMS document SPL files in the Electronic Common Technical Document (eCTD) can be found in the “eCTD Technical Conformance Guide.”

<table>
<thead>
<tr>
<th>Component of a REMS Submission</th>
<th>Submitted in SPL Format?</th>
</tr>
</thead>
<tbody>
<tr>
<td>REMS document</td>
<td>Yes</td>
</tr>
<tr>
<td>REMS supporting document</td>
<td>No</td>
</tr>
<tr>
<td>REMS materials</td>
<td>Referenced in SPL file</td>
</tr>
</tbody>
</table>

C. Types of Submissions That Are Exempt From the Electronic Submission Requirement Described in This Guidance

Section 745A(a) of the FD&C Act allows FDA to establish exemption and waiver criteria from the electronic submission requirements. For a discussion of current exemption and waiver criteria, please see Guidance for Industry, Providing Regulatory Submissions in Electronic Format—Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (Revision 7, February 2020).

D. SPL Specifications

Applicants must submit electronic submissions using the version of SPL currently supported by FDA as specified in the FDA Data Standards Catalog and further described in the SPL Implementation Guide.

E. Contact Information

For questions about providing electronic submissions according to the requirements in this guidance, you should contact FDA’s REMS Web site management team at FDAREMSwebsite@fda.hhs.gov. Specific questions about the content of applications should be directed to the appropriate review division or office.

9 For purposes of this guidance, a REMS supporting document is a document that expands on information in the REMS document and provides additional information about the REMS, such as the rationale for, and supporting information about, the design, implementation, and assessment of the REMS.
10 Available at: https://www.fda.gov/downloads/ForIndustry/DataStandards/StructuredProductLabeling/UCM321876.pdf
12 See SPL Implementation Guide for more information.
13 Available at: https://www.fda.gov/industry/fda-resources-data-standards.